A recent report has raised alarms about the pharmaceutical sector's exposure to a 'bubble effect' driven by the rapid growth in demand for weight loss and diabetes drugs.
The surge in popularity of treatments like Wegovy and Zepbound has led to a significant shift in the industry's focus, with obesity-related assets now accounting for a larger share of the late-stage drug pipeline than oncology, according to Deloitte.
The market implications of this trend are already being felt.
While the report does not directly attribute specific price movements, the broader sector has seen increased volatility as investors weigh the sustainability of this growth.
The pharmaceutical industry's reliance on a narrow set of high-demand products could expose it to sharp corrections if demand slows or regulatory hurdles emerge.
This development is part of a larger industry shift.